- •We describe the largest male breast cancer series with central pathology review.
- •Lobular breast cancer is rare in male.
- •Histological grade was not associated with outcome, unlike what is known in females.
- •Mitotic-index, presence of fibrosis and lymphocytes correlated with outcome.
Several prognostic histological features have been established in female breast cancer (BC), but it is unknown whether these can be extrapolated to male BC patients. The aim of this study was to evaluate the prognostic value of several histological features in a large series of male BC.
Central pathology review was performed for 1483 male BCs collected through part 1 of the European Organisation for Research and Treatment of Cancer (EORTC) International Male BC Program. Pathology review included histological subtype, grade, mitotic activity index (MAI), presence of a fibrotic focus and density of tumour-infiltrating lymphocytes (TILs). These features were correlated with clinical outcome. The relationship between these features and surrogate molecular subtypes using immunohistochemistry was also assessed.
Median follow-up for overall survival (OS) was 7.1 years. Overall histological grade was not significantly associated with OS (p = 0.129). MAI, the presence of a fibrotic focus and a low TIL density however were correlated with unfavourable OS (p = 0.023, p = 0.004 and p = 0.011, respectively). BC subtype correlated with TIL density (p = 0.015), as we observed a higher density for human epidermal growth factor receptor type 2 (HER2) positive BC compared to luminal HER2-negative subtype. No association was observed between subtype and fibrotic focus.
Histologic grade was not significantly correlated with clinical outcome in this series, unlike what is seen in female patients. These results contribute to our understanding of male BC and indicate the importance of further research on the optimisation of risk stratification and treatment decisions for male BC patients.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cancer statistics, 2015.CA Cancer J Clin. 2015; 65: 5-29
- Male breast cancer: a population-based comparison with female breast cancer.J Clin Oncol. 2010; 28: 232-239
- Breast carcinoma in men: a population-based study.Cancer. 2004; 101: 51-57
- Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification.Breast Cancer Res Treat. 2012; 135: 49-58
- Analysis of copy number changes on chromosome 16q in male breast cancer by multiplex ligation-dependent probe amplification.Mod Pathol. 2013; 26: 1461-1467
- Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification.Breast Cancer Res. 2012; 14: R101
- High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer.Breast Cancer Res Treat. 2011; 129: 747-760
- Molecular subtyping of male breast cancer by immunohistochemistry.Mod Pathol. 2012; 25: 398-404
- Molecular profiling of male breast cancer – lost in translation?.Int J Biochem Cell Biol. 2014; 53: 526-535
- A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences.Breast Cancer Res Treat. 2012; 133: 949-958
- Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival.Ann Epidemiol. 2005; 15: 773-780
- Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness.Jpn J Cancer Res. 1996; 87: 385-394
- Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation.Jpn J Cancer Res. 1997; 88: 590-599
- Different patterns of inflammation and prognosis in invasive carcinoma of the breast.Histopathology. 2006; 48: 692-701
- The prognostic significance of lymphovascular invasion in invasive breast carcinoma.Cancer. 2012; 118: 3670-3680
- Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma.Eur J Cancer. 2006; 42: 357-362
- Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.Histopathology. 1991; 19: 403-410
- Histological grading of invasive breast carcinoma–a simplification of existing methods in a large conservation series with long-term follow-up.Histopathology. 2009; 55: 724-731
- Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program.Arch Pathol Lab Med. 2014; 138: 1048-1052
- Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases.Crit Rev Oncol Hematol. 2010; 73: 246-254
- Fibrotic focus in breast carcinomas: relationship with prognostic parameters and biomarkers.Ann Surg Oncol. 2013; 20: 2842-2849
- The fibrotic focus in advanced colorectal carcinoma: a hitherto unrecognized histological predictor for liver metastasis.Virchows Arch. 1998; 433: 517-522
- Advanced pancreatic ductal cancer: fibrotic focus and beta-catenin expression correlate with outcome.Pancreas. 2003; 26: 326-333
- Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study.Mod Pathol. 2002; 15: 502-516
- Role of inflammatory infiltrates in triple negative breast cancer.J Clin Pathol. 2015; 68: 506-510
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.Ann Oncol. 2015; 26: 259-271
- Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.J Clin Oncol. 2014; 32: 2959-2966
- Prognostic factors in node-negative male breast cancer.Clin Breast Cancer. 2006; 7: 331-335
- Fibrotic focus and hypoxia in male breast cancer.Mod Pathol. 2012; 25: 1397-1404
- Characterization of male breast cancer: first results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program.Cancer Res. 2015; 75 (S6–S05-S6-05)
- Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Mod Pathol. 1998; 11: 155-168
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.J Clin Oncol. 2013; 31: 3997-4013
- A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation.Histopathology. 2007; 51: 440-451
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.Ann Oncol. 2013; 24: 2206-2223
- Invasive carcinomas of the male breast: a morphologic study of the distribution of histologic subtypes and metastatic patterns in 778 cases.Virchows Arch. 2006; 449: 507-512
- Associations of breast cancer risk prediction tools with tumor characteristics and metastasis.J Clin Oncol. 2016; 34: 251-258
- Is there ‘progression through grade’ in ductal invasive breast cancer?.Breast Cancer Res Treat. 2012; 135: 693-703
- Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.J Clin Oncol. 2013; 31: 860-867
Published online: March 12, 2017
Accepted: January 31, 2017
Received: January 30, 2017
© 2017 Elsevier Ltd. All rights reserved.